Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone-Reference-Cited by-同舟云学术

Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone

Published:2016-01-02 Issue:1 Volume:26 Page:36-45
ISSN:1537-6516
Container-title:Toxicology Mechanisms and Methods
language:en
Short-container-title:Toxicology Mechanisms and Methods

Author:

Xiao Yingying,Zhu Yewei,Yu Suhong,Yan Cuicui,J. Y. Ho Rodney,Liu Jian,Li Tao,Wang Jie,Wan Liyuan,Yang Xingtian,Xu Huo,Wang Jichuang,Tu Xiaohuang,Jia Lee

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Toxicology

Link

http://www.tandfonline.com/doi/pdf/10.3109/15376516.2015.1118715

Reference23 articles.

1. A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486)

2. The Unique Pharmacological Characteristics of Mifepristone (RU486): From Terminating Pregnancy to Preventing Cancer Metastasis

3. Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics

4. Cell Surface Molecules and Their Prognostic Values in Assessing Colorectal Carcinomas

5. Distribution of RU 486 and Its Demethylated Metabolites in Humans*

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression;Free Radical Biology and Medicine;2024-09

2. Prediction of chemical-induced acute toxicity using in vitro assay data and chemical structure;Toxicology and Applied Pharmacology;2024-09

3. Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer;Cancer Letters;2024-02

4. Estradiol dominance induces hemodilution and mild hematological alterations in mifepristone-treated rats;The Journal of Toxicological Sciences;2022

5. Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview;Clinical Pharmacokinetics;2021-09-27